FIGURE

Fig. 4

ID
ZDB-FIG-251104-13
Publication
Mero et al., 2025 - HPDL Biallelic Variants in Cerebral Palsy and Childhood-Onset Hereditary Spastic Paraplegia: Human and Zebrafish Insights
Other Figures
All Figure Page
Back to All Figure Page
Fig. 4

Drug tests. (A) Analysis of reactive oxygen species (ROS) production in two 4-hydroxyphenylpyruvate dioxygenase-like protein (HPDL) patients' fibroblasts after 1 week of treatment with 4-hydroxybenzoic acid (4HB) 1 mM and 4-hydroxymandelic acid (4HMA) 5 mM. Data showed a significant effect of 4HMA on ROS production, while no effects of 4HB treatment were observed. Data are the averages of two experiments. (B) 4HB 1 μM treatment improved burst activity of hpdl-F0 embryos versus controls; 4HMA 5 μM treatment normalized the phenotype of hpdl-F0 embryos (controls, n = 114; controls+4HB, n = 115; controls+4HMA, n = 51 hpdl-F0, n = 85; hpdl-F0+4HB, n = 74; hpdl-F0+4HMA, n = 42). (C) Locomotor behavior (distance moved and velocity) of hpdl-F0 versus controls at 5 dpf (days post-fertilization) was rescued with 4HMA 5 μM treatment, but not with 4HB 1 μM treatment (controls, n = 107; controls+4HB, n = 114; controls+4HMA, n = 111 hpdl-F0, n = 69; hpdl-F0+4HB, n = 57; hpdl-F0+4HMA, n = 44). In all graphs, asterisks denote statistically significant differences: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001, whereas “ns” indicates non-significant results.

Expression Data

Expression Detail
Antibody Labeling
Phenotype Data
Fish:
Conditions:
Knockdown Reagent:
Observed In:
Stage Range: Prim-15 to Day 5

Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Mov. Disord.